Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.54 |
| ▸ | CTSS | P25774 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 3/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 1/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17011363 | 1.00 | CTSK (0.54) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL3180779 | 1.00 | CTSK (0.54) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL29874941 | 1.00 | CTSK (0.54) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL3731957 | 0.87 | CTSK (0.46) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL15488335 | 0.86 | CTSK (0.57) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL3189254 | 0.86 | CTSK (0.57) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL15488043 | 0.86 | CTSK (0.57) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL21767271 | 0.86 | CTSK (0.57) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL3733675 | 0.85 | CTSK (0.44) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL28469457 | 0.85 | CTSK (0.55) | CTSKCTSSCA2CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070276-A | Prodrugs of xanomeline, prodrugs of trospium chloride and methods of using the same | 人类生物科学股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260124190-A1 | METHOD FOR TREATING A DISEASE OR CONDITION USING A PYRAZOLE COMPOUND OR FORMULATION THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12590065-B2 | Levorphanol prodrugs and processes for making and using them | ZEVRA THERAPEUTICS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4705289-A1 | PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF | Terran Biosciences Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCE INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12441723-B2 | Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations | RIGEL PHARMACEUTICALS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-12404262-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4605393-A1 | TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-08-27 | — | — | EP | disclosed |
| US-12357623-B2 | Method for treating a disease or condition using a pyrazole compound or formulation thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| CN-120077046-A | Triazole-substituted imidazo [1,2-A ] pyrimidines as CGAS inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-4139703-A | ANTIBIOTICS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 1979-02-13 | — | — | US | disclosed |
| US-4122260-A | CONTAINING FORMYL SUBSTITUTED PYRROLE, ANTIBIOTICS | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 1978-10-24 | — | — | US | disclosed |
| US-4118562-A | ANTIBIOTICS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 1978-10-03 | — | — | US | disclosed |
| US-4093804-A | ANTIBIOTICS | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 1978-06-06 | — | — | US | disclosed |
| US-4093802-A | ANTIBIOTICS | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 1978-06-06 | — | — | US | disclosed |
| US-4045438-A | Cephalosporin antibiotics | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 1977-08-30 | — | — | US | disclosed |
| US-4031083-A | Cephalosporin antibiotics | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 1977-06-21 | — | — | US | disclosed |
| US-4026887-A | Cephalosporin antibiotics | YEDA RESEARCH & DEVELOPMENT CO. LTD. (IL) | 1977-05-31 | — | — | US | disclosed |
| US-3994875-A | CEPHALOSPORINS, PENICILLINS | YEDA RESEARCH & DEVELOPMENT CO. LTD. (IL) | 1976-11-30 | — | — | US | disclosed |
| US-3948904-A | ANTIBIOTICS | YEDA RESEARCH & DEVELOPMENT CO. LTD. (IL) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441723-B2 | Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations | IRAK1, IRAK3, IRAK2 | CTSK 2338/4885CTSS 4194/4885CA2 4663/4885 |
| US-12357623-B2 | Method for treating a disease or condition using a pyrazole compound or formulation thereof | MCL1, IL5, MALT1 | CTSK 740/4885CTSS 2011/4885CA2 4799/4885 |
| US-12590065-B2 | Levorphanol prodrugs and processes for making and using them | SLC16A3, SLC16A8, SLC16A1 | CTSK 2835/4885CTSS 1409/4885CA2 321/4885 |
| US-12404262-B2 | Therapeutic compounds for HIV virus infection | HAVCR2, MAVS, CD4 | CTSK 498/4885CTSS 176/4885CA2 4777/4885 |
| US-20260124190-A1 | METHOD FOR TREATING A DISEASE OR CONDITION USING A PYRAZOLE COMPOUND OR FORMULATION THEREOF | IRAK2, IRAK3, IRAK1 | CTSK 2549/4885CTSS 3142/4885CA2 4037/4885 |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | CCR10, CCR1, CCR3 | CTSK 2915/4885CTSS 1749/4885CA2 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.